Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TA-CD. Xenova.

Christine E Heading1

  • 1Department of Biological Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK. moore11@globalnet.co.uk

Idrugs : the Investigational Drugs Journal
|June 12, 2003
PubMed
Summary
This summary is machine-generated.

TA-CD, a novel cocaine vaccine, is being developed to treat cocaine dependence by stimulating antibody production against cocaine. Clinical trials are ongoing to evaluate its efficacy and safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender issues and the pharmacotherapy of substance abuse.

IDrugs : the investigational drugs journal·2008
Same author

Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.

Current opinion in investigational drugs (London, England : 2000)·2007
Same author

Vivitrex (Alkermes/Cephalon).

Current opinion in investigational drugs (London, England : 2000)·2006
Same author

Conus toxins: targets and properties.

IDrugs : the investigational drugs journal·2004
Same author

NicVAX (Nabi Biopharmaceuticals).

IDrugs : the investigational drugs journal·2003
Same author

Recent advances against substance abuse.

IDrugs : the investigational drugs journal·2003

Area of Science:

  • Pharmacology
  • Immunology
  • Addiction Medicine

Background:

  • Cocaine dependence is a significant public health issue with limited treatment options.
  • Developing effective therapeutic interventions for substance use disorders is a priority.
  • Vaccine-based therapies offer a novel approach to treating addiction.

Purpose of the Study:

  • To evaluate the development of TA-CD (formerly IPC-1010) as a potential treatment for cocaine dependence.
  • To assess the ability of TA-CD to elicit an antibody response against cocaine.
  • To determine the safety and efficacy of TA-CD through clinical trials.

Main Methods:

  • TA-CD, a cocaine conjugate vaccine, was developed to induce antibodies against cocaine.
  • Pre-clinical and clinical studies were conducted to assess the vaccine's immunogenicity and therapeutic potential.

Related Experiment Videos

  • Phase IIa dose escalation trials were initiated to further evaluate the vaccine.

    • Main Results:

    • TA-CD is designed to stimulate the production of antibodies that bind to cocaine.
    • The vaccine has undergone development and licensing transfers, involving multiple institutions.
    • A Phase IIa clinical trial was underway to assess dose escalation by September 2002.

    Conclusions:

    • TA-CD represents a promising vaccine-based strategy for the potential treatment of cocaine dependence.
    • Further clinical evaluation is necessary to establish the definitive efficacy and safety profile of TA-CD.
    • The development of TA-CD highlights advancements in therapeutic vaccines for substance use disorders.